Patient history
A 37-year-old woman with a known hypo-echogenic lesion in her liver underwent a surveillance magnetic resonance imaging (MRI) scan. A recent ultrasound was unable to diagnose the lesion, and therefore an MRI was arranged. The patient noticed difficulty in breathing immediately after the intravenous (IV) administration of gadolinium (Gd). There was no tongue swelling, rash, nausea, vomiting, cardiac symptoms or lightheadedness.
She was not taking any regular medications and had no known allergies. She reported previously feeling 'light-headed' after the injection of iodinated contrast.
On initial examination in the radiology department, the patient was talking in full sentences, alert and orientated and maintaining her airway, with no tongue or lip swelling. Her oxygen saturations were 98% on air with a respiratory rate (RR) of 18 breaths/minute. The pulse was 105 beats per minute and regular, blood pressure was 87/52 mm Hg and the jugular venous pressure was not elevated. Her temperature was 38°C. Initial arterial blood gas (ABG) on air showed pH 7.409, PaCO 2 4.0 kPa, PaO 2 14.40 kPa, PaO 2 :FiO 2 ratio 68 kPa (510 mm Hg), (Figure 1 ), base excess (BE) -4.7 mmol/L and lactate 1.4 mmol/L.
In view of the symptoms of dyspnoea, low BP and pyrexia, an anaphylactoid reaction was suspected and she was given intravenous fluids, hydrocortisone and chlorphenamine IV by the radiology staff. The patient was then transferred to the emergency department for further monitoring.
Two hours later, the patient developed further dyspnoea,
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We present the rare case of a 37-year-old female presenting with acute respiratory distress syndrome (ARDS) following administration of gadolinium (Gd) chelate during a magnetic resonance imaging (MRI) liver scan. with increasing oxygen requirements. Bibasal crackles were present on auscultation of the chest. On examination, her pulse was 122 bpm, BP 100/66, RR 20 breaths/min and temperature 37.9°C. A plain chest X-ray (CXR) demonstrated extensive bilateral round pulmonary infiltrates (Figure 2 ). Repeat ABGs with FiO 2 of 0.5 showed pH 7.395, PaCO 2 4.4 kPa, PaO 2 11.8 kPa, BE -3.7, lactate 3.8, PaO 2 :FiO 2 23.6 kPa (177 mm Hg). Electrocardiogram showed normal sinus rhythm with no ischaemic changes. A diagnosis of acute lung injury (ALI) of uncertain aetiology was made and the patient was started on continuous positive airway pressure (CPAP) with 5 cm H 2 O PEEP and FiO 2 0.5 via a tight-fitting face mask and she was transferred to the intensive care unit (ICU).
An infective cause was thought to be unlikely, as although the white cell count (WCC) was elevated at 16.9 x 10 9 /L, the C-reactive protein of 10 mg/L was low and there was no other evidence of infection (negative urine dipstick, no sputum production, abdominal pain, recent illnesses or positive examination findings). The WCC returned to normal within 36 hours (9.2 x 10 9 /L). There was no evidence of other common risk factors for ALI such as gastric aspiration, fat embolus, inhalational injury or massive transfusion. Pulmonary oedema of a cardiac cause was thought to be unlikely, as the patient was a previously fit and healthy woman of child-bearing age with no risk factors or symptoms for cardiac disease or failure. Further cardiac investigations were felt to be unwarranted.
In view of the lack of other positive investigations, the IV gadolinium was felt to be the cause of the mild ARDS as defined by the Berlin 2012 criteria 1 (see Figure 1 ).
Over the next thirty-six hours she improved significantly and did not require invasive ventilation or other organ support. The patient made a full recovery and was discharged home.
Discussion
In summary, water-soluble Gd-chelates are used as the primary non-iodinated contrast in MRI. Gd-chelates have similar adverse events to those seen with iodinated contrast agents. 2 However, events are much less common and mostly minor, with rates ranging from 0.07% 1 -2.4%, and with only 7% of 0.07% experiencing severe symptoms, 3 compared to iodinated contrast media. ALI is very rare. [2] [3] [4] [5] [6] [7] Adverse reactions are more common in atopic patients or in
patients with a history of asthma or atopia, with rapid injection of the contrast agent and/or a history of Gd-based or iodinated contrast agent allergy. 4 This patient had a history of some lightheadedness with iodinated contrast media previously, but had no evidence of an allergic reaction. The classification of adverse events varies, with no universally acknowledged categorisation available. Dillman et al 5 categorise adverse reactions as follows:
• mild: pruritus, rash, urticaria, cough, nasal stuffiness, sneezing, mild eye/facial swelling • moderate: dyspnoea, bronchospasm, mild laryngeal oedema, symptomatic tachycardia/bradycardia, hypo/hypertension • Severe: severe respiratory distress, loss of consciousness, convulsions, arrhythmia, progressive angioedema, and cardiopulmonary arrest. 6 Another classification uses non-allergic versus idiosyncratic, allergic-like reactions. 6 Non-allergic reactions may be seen with headache, fatigue, arthralgia, taste perversion, flushed feeling, nausea or vomiting, as opposed to idiosyncratic allergy-like reactions with hives, diffuse erythema, respiratory distress, chest tightness, respiratory distress and peri-orbital oedema. Hunt et al 7 defined severe reactions as cardiovascular collapse, moderate or severe bronchospasm, laryngeal oedema, loss of consciousness and seizures. This patient falls into the idiosyncratic, allergy-like reaction of respiratory distress.
In evaluations of Gd-related adverse reactions, women had more reactions than men, which may in part be due to a greater number of women receiving contrast. 5, 7 Other patients at risk include those with renal failure 8 or with a history of anaphylactoid reactions. Asthmatics have double the risk, even if their disease is under control, and patients with multiple allergies to food or medications are also at higher risk.
While rare, it is important for intensive care physicians to recognise Gd-chelates can cause ALI, while at the same time excluding other, more common, causes. As most MRIs are performed in an isolated environment, it is important to recognise potentially life-threatening events are possible, to ensure early treatment. It is also important to recognise that not all adverse reactions to intravenous agents are anaphylactoid in nature. The aim of this redefinition of the initial ARDS criteria from 1994 2 was to address a number of issues that had emerged subsequent to their publication: • ARDS was initially defined as being of 'acute' or 'sudden onset' but the exact timing was not specified. This has now been deemed to occur within a week. • The initial description of 'bilateral infiltrates' was on frontal chest radiograph alone and was subject to high interobserver variability in interpretation. This description has been expanded to recognise that these findings could also be identified on CT scan, and example radiographs have also been made available. • The exclusion of cardiogenic pulmonary oedema was initially made on demonstrating a pulmonary capillary wedge pressure (PCWP) of <18 mm Hg, but right heart catheterisation is currently used much less frequently, 3 and cardiogenic pulmonary oedema can co-exist with ARDS, both of which can cause high PCWP. 4 Subsequently, the wedge pressure requirement has been removed and where no risk factors for ARDS exist, objective exclusion of hydrostatic pulmonary oedema needs to be performed with, for example, echocardiography. • Finally, the P:F ratio has been found to be sensitive to changes in ventilator settings, such that a PaO 2 response to increasing PEEP allowed discrimination of patients into two distinct groups in terms of severity and outcome. 5 In addition, a situation could previously arise where a patient would fit ALI/ARDS criteria at one level of PEEP but not another. To circumvent this, a minimal PEEP level was specified across the groups and the term 'acute lung injury' (ALI) was abandoned in favour of three levels of severity of ARDS based on the subsequent P:F ratio. ALI had been used inconsistently in the literature, sometimes referring correctly to patients with a P:F ratio of 200-300 mm Hg but often articulated to a broader group of patients including those with ARDS. Using the terms 'mild', 'moderate' and 'severe' ARDS would simplify nomenclature and improve patient stratification -particularly as recent trials show outcome benefit in the use of PEEP and prone positioning in 'severe' ARDS. [6] [7] [8] Clearly, there are still limitations of the definition; in specifying a minimal PEEP level, ARDS in non-ventilated patients no longer exists as a clinical entity and this patient cohort will subsequently be excluded from trials that they may have previously been enrolled in, and clinically may not receive care bundles previously developed for them. In addition, although an improvement over the previous definition, it remains a poor predictor of death, with an area under the receiver-operating curve of 0.57% vs 0.536% for the AECC definition, 1 probably because death is driven by non-ARDSrelated factors. However, the consensus draft definition has addressed and rectified some key concerns with the previous definition.
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Gadolinium-induced ARDS has been described as a clinical entity only recently. The other reported case resulted in severe respiratory failure requiring extra-corporeal membrane oxygenation. 9 Of note in both cases, there was resolution of symptoms within a short time window corroborating the contrast agent as a potential aetiological agent, but also demonstrating that even severe ARDS as an entity has a variable prognosis related to its underlying cause, and supportive treatment can result in good outcomes even in severe cases.
